Huang Yiyong,Yang Ge,Liu Yaoxi,et al.Proteomic analysis of serum-derived exosomes from congenital pseudarthrosis of tibia[J].Journal of Clinical Pediatric Surgery,,21():551-557.[doi:10.3760/cma.j.cn101785-202102043-010]
Proteomic analysis of serum-derived exosomes from congenital pseudarthrosis of tibia
- Keywords:
- Congenital Pseudarthrosis of Tibia; Tibia/AB; Pseudarthrosis/CN; Proteomics/CL; Proteomics/MT; Exosomes
- Abstract:
- Objective To explore the possible pathogenesis of congenital pseudarthrosis of tibia (CPT) through compare the differential protein expression in serum-derived exosomes (SDEs) between CPT and normal children.Methods SDEs were extracted from venous plasma of 6 CPT children and 4 normal controls.Then differentially expressed proteins were examined by tandem mass tag (TMT)-based proteomics.And proteomic information was acquired through Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, gene ontology (GO) classification, DisGeNET enrichment analysis and protein-protein interaction (PPI) enrichment analysis.Results Based upon proteomics analysis, 121 up-regulated and 289 down-regulated proteins were identified.Complement & coagulation cascade was the most obvious enrichment in KEGG pathway.Monosaccharide metabolic process was one of enriched process during the biological process of gene ontology (GO) classification.DisGeNET enrichment analysis indicated that three of top five diseases were associated with osteoporosis.And glycolysis/gluconeogenesis was a part of enriched terms during PPI enrichment analysis.It hinted that complement and glycolysis/gluconeogenesis were abnormal in CPT.Conclusion Abnormality of complement and glycolysis/gluconeogenesis might be a potential pathogenic mechanism of CPT.Also this study may provide new rationales for exploring the etiology and pathogenesis of CPT.
References:
[1] Kesireddy N, Kheireldin RK, Lu A, et al.Current treatment of congenital pseudarthrosis of the tibia:a systematic review and meta-analysis[J].J Pediatr Orthop B, 2018, 27(6):541-550.DOI:10.1097/BPB.0000000000000524.
[2] Pina ME, Veiga F.The influence of diluent on the release of theophylline from hydrophilic matrix tablets[J].Drug Dev Ind Pharm, 2000, 26(10):1125-1128.DOI:10.1081/ddc-100100279.
[3] Zhu G, Zheng Y, Liu Y, et al.Identification and characterization of NF1 and non-NF1 congenital pseudarthrosis of the tibia based on germline NF1 variants:genetic and clinical analysis of 75 patients[J].Orphanet J Rare Dis, 2019, 14(1):221.DOI:10.1186/s13023-019-1196-0.
[4] 汤用波, 梅海波.先天性胫骨假关节的病因学研究进展[J].临床小儿外科杂志, 2013, 12(3):234-236, 254.DOI:10.3969/j.issn.1671-6353.2013.03.023.Tang YB, Mei HB.Research etiological advances of congenital pseudarthrosis of tibia[J].J Clin Ped Sur, 2013, 12(3):234-236, 254.DOI:10.3969/j.issn.1671-6353.2013.03.023.
[5] 朱光辉, 梅海波, 刘昆, 等.OPG及RANKL在儿童先天性胫骨假关节病变骨与骨膜中的表达研究[J].临床小儿外科杂志, 2019, 18(4):331-334.DOI:10.3969/j.issn.1671-6353.2019.04.017.Zhu GH, Mei HB, Liu K, et al.Expressions of OPG and RANKL in tibia bone and periosteum of congenital tibial pseudarthrosis of the tibia in children[J].J Clin Ped Sur, 2019, 18(4):331-334.DOI:10.3969/j.issn.1671-6353.2019.04.017.
[6] Cheng C, Shoback D.Mechanisms underlying normal fracture healing and risk factors for delayed healing[J].Curr Osteoporos Rep, 2019, 17(1):36-47.DOI:10.1007/s11914-019-00501-5.
[7] Bahney CS, Zondervan RL, Allison P, et al.Cellular biology of fracture healing[J].J Orthop Res, 2019, 37(1):35-50.DOI:10.1002/jor.24170.
[8] Madhuri V, Mathew SE, Rajagopal K, et al.Does pamidronate enhance the osteogenesis in mesenchymal stem cells derived from fibrous hamartoma in congenital pseudarthrosis of the tibia?[J].Bone Rep, 2016, 5:292-298.DOI:10.1016/j.bonr.2016.10.003.
[9] Cho TJ, Seo JB, Lee HR, et al.Biologic characteristics of fibrous hamartoma from congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1[J].J Bone Joint Surg Am, 2008, 90(12):2735-2744.DOI:10.2106/JBJS.H.00014.
[10] Ippolito E, Corsi A, Grill F, et al.Pathology of bone lesions associated with congenital pseudarthrosis of the leg[J].J Pediatr Orthop B, 2000, 9(1):3-10.DOI:10.1097/01202412-200001000-00002.
[11] Meldolesi J.Exosomes and ectosomes in intercellular communication[J].Curr Biol, 2018, 28(8):R435-R444.DOI:10.1016/j.cub.2018.01.059.
[12] Xie Y, Gao Y, Zhang L, et al.Involvement of serum-derived exosomes of elderly patients with bone loss in failure of bone remodeling via alteration of exosomal bone-related proteins[J].Aging Cell, 2018, 17(3):e12758.DOI:10.1111/acel.12758.
[13] Yang G, Yu H, Liu Y, et al.Serum-derived exosomes from neurofibromatosis type 1 congenital tibial pseudarthrosis impaired bone by promoting osteoclastogenesis and inhibiting osteogenesis[J].Exp Biol Med (Maywood), 2021, 246(2):130-141.DOI:10.1177/1535370220962737.
[14] Eisenberg KA, Vuillermin CB.Management of congenital pseudoarthrosis of the tibia and fibula[J].Curr Rev Musculoskelet Med, 2019, 12(3):356-368.DOI:10.1007/s12178-019-09566-2.
[15] Andrades JA, Nimni ME, Becerra J, et al.Complement proteins are present in developing endochondral bone and may mediate cartilage cell death and vascularization[J].Exp Cell Res, 1996, 227(2):208-213.DOI:10.1006/excr.1996.0269.
[16] Lee AR, Moon DK, Siregar A, et al.Involvement of mitochondrial biogenesis during the differentiation of human periosteum-derived mesenchymal stem cells into adipocytes, chondrocytes and osteocytes[J].Arch Pharm Res, 2019, 42(12):1052-1062.DOI:10.1007/s12272-019-01198-x.
[17] Tikkanen J, Leskel? HV, Lehtonen ST, et al.Attempt to treat congenital pseudarthrosis of the tibia with mesenchymal stromal cell transplantation[J].Cytotherapy, 2010, 12(5):593-604.DOI:10.3109/14653249.2010.487898.
[18] Antebi B, Pelled G, Gazit D.Stem cell therapy for osteoporosis[J].Curr Osteoporos Rep, 2014, 12(1):41-47.DOI:10.1007/s11914-013-0184-x.
[19] Dilogo IH, Mujadid F, Nurhayati RW, et al.Evaluation of bone marrow-derived mesenchymal stem cell quality from patients with congenital pseudoarthrosis of the tibia[J].J Orthop Surg Res, 2018, 13(1):266.DOI:10.1186/s13018-018-0977-9.
Memo
收稿日期:2021-02-14。
基金项目:湖南省重点研发计划（2020SK2113）；湖南省儿童肢体畸形临床医学研究中心（2019SK4006）；湖南省出生缺陷协同防治科技重大专项（2019SK1010）
通讯作者:梅海波,Email:meihaibo@sohu.com